No Picture
News

Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Launched Phexxi(TM) (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free ContraceptionInitiated Pivotal Phase 3 EVOGUARD Trial of EVO100 for Prevention of Chlamydia and GonorrheaSecured $25 Million Strategic Investment from Adjuvan… […]

No Picture
News

Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sa… […]

No Picture
News

Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020

LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sa… […]

No Picture
News

Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials

CARLSBAD, Calif., Nov. 5, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen’s l… […]

No Picture
News

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended  September 30, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet p… […]